Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2
Dr Antonio Passaro reports on key results from ESMO Congress 2023 on LBA15 - Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated Advanced NSCLC After Progression on Osimertinib: MARIPOSA-2, a Phase 3, Global, Randomized, Controlled Trial
Produced by the European Society for Medical Oncology
http://oncologypro.esmo.org
Watch video Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2 online without registration, duration hours minute second in high quality. This video was added by user European Society for Medical Oncology (ESMO) 23 October 2023, don't forget to share it with your friends and acquaintances, it has been viewed on our site 1,627 once and liked it 12 people.